Axial VC

Stately Bio specializes in regenerative medicine technologies for therapeutic discovery and manufacturing. Its patented machine learning-based live-cell imaging system measures cell identity, behavior, and maturation directly from live cells without labels or dyes, facilitating non-invasive, real-time analysis of living cells.

AI research assistant for biology.

Insamo operates a biotechnology platform designed to pioneer the discovery of membrane-permeable and orally available cyclic peptides, exhibiting antibody-like binding affinity. Its automated process combines molecular biology and parallel synthetic chemistry to rapidly identify preclinical candidates with favorable pharmacological properties, enabling healthcare professionals to enhance patient care by replacing injected or infused biologics with easily administered oral cyclic-peptide formulations.

Founded in 2021, Aperiam Bio specializes in protein engineering. It partners with enzyme engineers and distributors to create stabilized, solubilized, and catalytically optimized proteins using computer vision algorithms and deep learning optimization.

Nalu Bio is a biotechnology company specializing in the chemical synthesis of cannabinoids (CBD), aiming to provide pure, safe ingredients that are environmentally sustainable. Unlike traditional plant-based methods, Nalu Bio's approach uses significantly less land, water, and energy, while maintaining high purity standards (0% THC) without relying on chemicals or pesticides.

Meliora Therapeutics is a biotech startup focused on developing innovative cancer therapies by leveraging a machine learning-driven platform. The company aims to identify the true mechanisms of action (MOA) of oncology medications through its proprietary prediction atlas, which maps drug mechanisms. This approach streamlines the drug development process by eliminating a significant and costly phase, thereby allowing researchers to advance their work more efficiently. By focusing on the precise actions of molecules of interest, Meliora Therapeutics seeks to enhance the effectiveness of cancer treatments and contribute to life-saving medical advancements in oncology.

Network Bio develops a platform that serves as a centralized repository for clinical and molecular data. This enables researchers to identify patterns and correlations, facilitating precision medicine approaches for common human diseases.

Think Bioscience is a company focused on advancing synthetic biology to enhance the development of medicines. It employs innovative technology to encode complex molecular objectives within microbial hosts, facilitating the identification, construction, and evolution of small molecules. By leveraging living systems, Think Bioscience aims to transform the drug discovery process, providing medical researchers with powerful tools to create better therapeutic solutions. The company's approach represents a significant evolution in the field of synthetic biology, positioning it as a leader in the quest for improved medicinal outcomes.

Replay is a genome writing company focused on advancing genomic medicine by reprogramming biological systems through the synthesis and delivery of large DNA constructs. The company aims to harness the potential of genome engineering to create innovative solutions in medicine, enhancing the ability to manipulate genetic material for therapeutic purposes. By developing technologies that enable precise DNA writing, Replay seeks to redefine the landscape of genetic research and its applications, ultimately contributing to improved health outcomes and the treatment of various diseases.

CHARM Therapeutics uses 3D deep learning and advanced drug discovery technologies to develop transformational medicines for diseases that are difficult to treat, aiming to enable clinicians to target undruggable disease targets with novel therapies that offer potentially life-changing efficacy.

Omica is Latin America's Biomedical Data Hub. We aggregate high quality datasets for Life Science R&D. Our platform consists of an AI-enhanced EMR system linked to a multi-omics biobank.

Adaptyv Bio is a biotechnology company focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company's innovative technology aims to identify new antibodies for the treatment of various diseases by bridging the gap between computational predictions and experimental validation. Through its advanced methodologies, Adaptyv Bio seeks to enhance the efficacy of therapeutic interventions, ultimately improving patient outcomes.

Founded in Menlo Park, California in 2019 by Aaron Mayer and Sunil Bodapati, Enable Medicine is a biotechnology company specializing in accelerating insight discovery through spatial biology data generation, management, and analysis on its cloud platform.

Zeit Medical is a company focused on advancing the treatment of neurological injuries through innovative technology. Founded in 2019 by Urs Naber and Orestis Vardoulis, the company has developed a specialized headband that continuously monitors the electrical activity of the brain. This device integrates smoothly with existing electroencephalogram (EEG) systems and automates the pre-screening process, facilitating the annotation of extensive datasets. By identifying signature patterns in EEG readings, Zeit Medical enables physicians to diagnose and treat neurological conditions with greater precision, particularly in detecting the onset of strokes.

Options MD is a telemedicine platform that employs AI-driven algorithms to match individuals with severe or treatment-resistant mental illnesses to personalized care options. It then connects these patients with in-house psychiatric experts for appropriate medical assistance.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Parallel Health is a skin health company that uses genomics, the skin microbiome, and machine learning to offer end-to-end dermatology solutions. It develops a precision health platform that combines microbial genomics, big data, and AI to enable skin testing, personalized microbiome products, and custom prescriptions for consumers, patients, and clinicians, integrating derm telehealth, microbiome diagnostics, and data-driven skincare therapies to address diverse skin conditions with tailored treatments.